TMCnet News
HCW Biologics' CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology (“CEB-2022”) taking place in Boston, Massachusetts on April 18-20, 2022 (https://cellexpbiol.unitedscientificgroup.org). Dr. Wong’s presentation entitled, “Bifunctional Immunotherapeutic HCW9218 for Cancer and Inflammaging,” will highlight preclinical data from in vivo animal studies demonstrating the ability of the Company’s lead investigational candidate, HCW9218, to both enhance the anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence (TIS) and eliminating TGF-ß and its immunosuppressive effects. The presentation will highlight information contained in a pivotal paper recently published in a peer-reviewed journal entitled, “Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell Mediated Reduction of Therapy Induced Senescent Cells.” Chaturvedi P., et al., Molecular Therapy, 2022; 30:1171-1187. Dr. Wong will also share for the first time preclinical data showing that HCW9218 is a promising senolytic and senomorphic agent for age-related pathologies. Dr. Wong stated, “Chemotherapies seed cancer relapses and metastases, and trigger inflammation-based side effects in treated patients by inducing cancer senescent cells and normal tissue cellular senescence. We have previously demonstrated, in preclinical studies, that HCW9218 can effectively reduce therapy-induced cancer and normal tissue cellular senescence to augment the anti-tumor activities of chemotherapies and alleviate their side effects. Thus, we believe HCW9218 can make chemotherapy cancer treatments work better with fewer side effects and extend the health span for cancer survivors. Now, we discovered that HCW9218 can also reduce accumulated senescent cells due to the naturally aging process or metabolic dysfunction leading to the improvement of heath span of experimental animals. I am thrilled to share this transformative discovery with the scientific community at the CEB-2022 conference.” In explaining why he selected CEB-2022 as the venue to feature HCW Biologics’ work on anti-inflammaging, Dr. Wong stated, “CEB-2022 is a gathering of scientific experts from around the world who come together to discuss innovation and advancement in the fields of cell and molecular biology. HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing the condition. The conference provides an audience who will be able to appreciate what we believe is a novel approach backed by breakthrough data.” HCW9218 will soon reach the clinical development stage for cancer. The Company expects to gain human data from two clinical trials that will guide the future development of HCW9218 for other age-related pathologies. (See ClinicalTrials.gov: HCW9218 for Advanced Pancreatic Cancer (NCT05304936) and HCW9218 in Select Advanced Solid Tumors (NCT05322408)). Dr. Wong will make his presentation at CEB-2022 on Tuesday, April 19, 2022, at 4:00 p.m. ET. The presentation will be available on HCW Biologics’ Investor Relations website. About HCW Biologics: Forward Looking Statements:
|